86-OR

Abstract

Objectives To analyze Endocan-1 levels (biomarker/predictor of vascular endothelial related pathologies) in maternal/fetal plasma and placentae in women with pre-eclampsia compared to normotensive controls, in the third trimester of pregnancy; and correlate de results with maternal and fetal data. Methods Endocan-1 levels were measured in maternal/fetal plasma and placentae from normotensive (n = 67) and pre-eclamptic (n = 50) women. It was quantified using MagPlexTH-C microspheres system and analyzed by ANCOVA adjusted by BMI, gestational age and maternal age. Finner-Bonferroni multiple testing was applied when pre-eclamptic group was stratified. To estimate the difference between groups, mean ratio (MR) and confidence interval (CI) of 95% was calculated. Analysis between Endocan-1 levels and maternal/fetal variables were made by Pearson correlation. The null hypothesis was rejected when p Results Higher levels of Endocan-1 were found in maternal plasma in pre-eclamptic group (MR = 1.49; 95% CI: 1.19–1.85, p = 0.001), with a moderate effect size (Cohen’s D = 0.84). No difference was found for fetal plasma and placenta. When pre-eclamptic group was stratified, maternal Endocan-1 levels were increased in all subgroups: gestational age, cutoff: 37 and 34 weeks (p = 0.002; p = 0.001); systolic blood pressure, cutoff: 160 mmHg (p = 0.002) and proteinuria, cutoff: 0.5 and 2.0 (p = 0.002, for both). Also, as higher Endocan-1 levels in maternal and fetal plasma, lower the newborn weights (pre-eclampsia: r = −0.42; normotensive: r = −0.281), placental weight (pre-eclampsia: r = −0.34; normotensive: r = −0.289) and gestational age at birth (pre-eclampsia: r = −0.382; normotensive: r = −0.260), p Conclusions Endocan-1 is a cytokine that reveals an endothelial activation. It was shown increased in patients with pre-eclampsia for all subgroups, which highlight the importance of the studying of this molecule throughout the gestational period, as a possible biomarker. The negative correlations between Endocan-1 and clinical data suggest that this molecule may also be involved with prematurity and low birth weight. Disclosures M.R. Hentschke: None. L.S. Lucas: None. H.D. D. Mistry: None. B.E. Pinheiro da Costa: None. C.E. Poli-de-Figueiredo: None.